GRI Bio, Inc. (GRI)
Total Valuation
GRI Bio has a market cap or net worth of $746,782. The enterprise value is -$2.71 million.
Market Cap | 746,782 |
Enterprise Value | -2.71M |
Important Dates
The next estimated earnings date is Monday, May 13, 2024, before market open.
Earnings Date | May 13, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
GRI Bio has 976,186 shares outstanding. The number of shares has increased by 360.26% in one year.
Shares Outstanding | 976,186 |
Shares Change (YoY) | +360.26% |
Shares Change (QoQ) | +70.59% |
Owned by Insiders (%) | 17.75% |
Owned by Institutions (%) | 4.60% |
Float | 367,144 |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.34 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.01, with a Debt / Equity ratio of 0.01.
Current Ratio | 2.01 |
Quick Ratio | n/a |
Debt / Equity | 0.01 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -13.52 |
Financial Efficiency
Return on equity (ROE) is -1,101.40% and return on invested capital (ROIC) is -536.90%.
Return on Equity (ROE) | -1,101.40% |
Return on Assets (ROA) | -410.70% |
Return on Capital (ROIC) | -536.90% |
Revenue Per Employee | n/a |
Profits Per Employee | -$12.86M |
Employee Count | 1 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.07% in the last 52 weeks.
Beta (1Y) | n/a |
52-Week Price Change | -99.07% |
50-Day Moving Average | 1.21 |
200-Day Moving Average | 11.03 |
Relative Strength Index (RSI) | 35.62 |
Average Volume (30 Days) | 740,344 |
Short Selling Information
The latest short interest is 115,733, so 11.86% of the outstanding shares have been sold short.
Short Interest | 115,733 |
Short Previous Month | 143,419 |
Short % of Shares Out | 11.86% |
Short % of Float | 31.52% |
Short Ratio (days to cover) | 0.08 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -12.11M |
Pretax Income | -12.86M |
Net Income | -12.86M |
EBITDA | -11.97M |
EBIT | -11.98M |
Earnings Per Share (EPS) | -$81.48 |
Balance Sheet
The company has $3.49 million in cash and $28,000 in debt, giving a net cash position of $3.46 million or $3.54 per share.
Cash & Cash Equivalents | 3.49M |
Total Debt | 28,000 |
Net Cash | 3.46M |
Net Cash Per Share | $3.54 |
Equity / Book Value | 2.23M |
Book Value Per Share | 2.28 |
Working Capital | 2.19M |
Cash Flow
In the last 12 months, operating cash flow was -$4.80 million and capital expenditures -$8,000, giving a free cash flow of -$4.81 million.
Operating Cash Flow | -4.80M |
Capital Expenditures | -8,000 |
Free Cash Flow | -4.81M |
FCF Per Share | -$8.16 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
GRI Bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -360.26% |
Shareholder Yield | -360.26% |
Earnings Yield | -1,722.32% |
FCF Yield | -643.96% |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on January 30, 2024. It was a reverse split with a ratio of 1:7.
Last Split Date | Jan 30, 2024 |
Split Type | Reverse |
Split Ratio | 1:7 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |